Companies
9,600+ pipelines, each resolved to the company that owns it today
Coverage
- 9,600+ company pipelines, from preclinical programs through clinical-stage trials.
- Normalized companies from trial sponsors, product labellers, and name variants, resolved into one record per company.
- 2,300+ parent-to-subsidiary chains resolved by engineering company hierarchies, with relationships labelled as an absorbed subsidiary, an independent subsidiary, or a merger.
Where it connects
Company record
Pfizer
Drugs
Every asset the company owns, at every stage
namePalbociclib
drugbank_idDB09073
approval_statusapproved, investigational
+775 more assets
Clinical trials
Every trial the company sponsors, under any of its names
trialNCT04993677
sponsors.title (as filed)Seagen Inc.absorbed subsidiary
companies.namePfizer
5,467 trials rolling up to Pfizer, 1,164 of them filed under another company’s name
Targets
The biology its portfolio acts on, through the drugs that bind it
drugBHV-7000
proteinPotassium voltage-gated channel subfamily KQT member 2
targetKCNQ2
uniprot_idO43526
modulation_typeactivation
+102 more proteins across Pfizer’s programs
Diseases
A portfolio’s therapeutic focus
indicationtinnitus
conditionTinnitus, Spontaneous Oto-Acoustic Emission
drugbank_idDBCOND0068067
indication_kindtreatment_of
disease_areasOtorhinolaryngologic Diseases
+2 more disease areas
Zoom in
| sponsors.title | companies.name | relationship_type |
|---|---|---|
| Seagen Inc. | Seagen | absorbed_subsidiary |
| Wyeth is now a wholly owned subsidiary of Pfizer | Wyeth | absorbed_subsidiary |
| Pharmacia and Upjohn | Pharmacia | absorbed_subsidiary |
| Biohaven Therapeutics Ltd. | Biohaven | absorbed_subsidiary |
| Arena Pharmaceuticals | Arena Pharmaceuticals | independent_subsidiary |
| King Pharmaceuticals is now a wholly owned subsidiary of Pfizer | King Pharmaceuticals | merger |
+35 more names
| program_drugbank_id | name | target | indication | raw_status |
|---|---|---|---|---|
| DBPRG00156843 | opakalim for tinnitus | Potassium voltage-gated channel subfamily KQT member 2 | Tinnitus, Spontaneous Oto-Acoustic Emission | active |
| DBPRG00171171 | BHV-8200 for Parkinson's disease | Alpha-synuclein | Parkinson's Disease (PD) | active |
| DBPRG00154389 | BHV-1440 for Graves' disease | Thyrotropin receptor | Graves Disease (Basedow's Disease) | active |
| DBPRG00133641 | BHV-1420 for membranous nephropathy | Secretory phospholipase A2 receptor | Membranous Nephropathy | active |
| DBPRG00172892 | [unnamed 35-valent pneumococcal vaccine candidate] for pneumococcal disease | [] | Pneumococcal Infection | [] |
| DBPRG00061331 | [unnamed entity] for [unspecified condition] | Tyrosine-protein kinase JAK1 | [] | discontinued |
+498 more programs
| program_drugbank_id | category | date_kind | raw_kind | raw_date | event_date |
|---|---|---|---|---|---|
| DBPRG00136749 | preclinical_milestone | actual | Preclinical data presentation | September 10, 2024 | 2024-09-10 |
| DBPRG00118331 | regulatory_submission | actual | Regulatory interaction with FDA | first half of 2025 | 2025-01-01 |
| DBPRG00144090 | preclinical_milestone | actual | IND-enabling studies initiated | [] | 2025-03-26 |
| DBPRG00067975 | business_decision | actual | Preclinical development paused | [] | 2024-11-12 |
| DBPRG00090731 | clinical_milestone | anticipated | Phase 2 initiation | 2024 | [] |
| DBPRG00118298 | regulatory_submission | anticipated | IND submission | 2025 | [] |
+199 more events
| conditions.title | disease_areas | programs |
|---|---|---|
| Sickle Cell Disease | Hemic and Lymphatic Diseases; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Cardiovascular Diseases | 36 |
| Beta-Thalassemia | Hemic and Lymphatic Diseases; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Cardiovascular Diseases | 31 |
| Malignant Neoplasms | Neoplasms | 20 |
| Frontotemporal Lobar Degeneration (FTLD) | Nutritional and Metabolic Diseases; Mental Disorders; Nervous System Diseases; Congenital, Hereditary, and Neonatal Diseases and Abnormalities | 18 |
| Coronavirus Disease 2019 (COVID-19) | Infections | 15 |
| Immunoglobulin A Nephropathy | Urogenital Diseases; Immune System Diseases | 14 |
| Inflammatory Bowel Diseases (IBD) | Digestive System Diseases; Infections | 12 |
| Parkinson's Disease (PD) | Nutritional and Metabolic Diseases; Mental Disorders; Nervous System Diseases | 11 |
Questions it answers
- Which of an acquirer’s pipelines overlap with ours? Landscape and whitespace analysis
- What is a competitor working on before it reaches a trial registry? Competitive clinical landscape
- Which deprioritized or divested assets in our area could be licensed? Landscape and whitespace analysis
All figures pulled as of November 2026.